Alkermes plc. (ALKS) Cash and securities
- Total cash · latest quarter (USD): Value $656.58M; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $656.58M | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $511.53M + $145.05M ≈ $656.58M |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 511.53M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 145.05M USD | Debt Securities, Available-for-sale, Current |
| Cash and current securities | 656.58M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $656.58M | (m) | $511.53M | $145.05M | (m) |
| 2026-03-31 | $511.86M | (m) | $351.55M | $160.31M | (m) |
| 2025-12-31 | $588.22M | (m) | $388.57M | $199.65M | (m) |
| 2025-09-30 | $1.11B | (m) | $616.45M | $494.67M | (m) |
| 2025-06-30 | $1.02B | (m) | $521.20M | $494.54M | (m) |
| 2025-03-31 | $884.02M | (m) | $399.81M | $484.21M | (m) |
| 2024-12-31 | $751.67M | (m) | $291.15M | $460.52M | (m) |
| 2024-09-30 | $908.86M | (m) | $396.29M | $512.57M | (m) |
| 2024-06-30 | $876.12M | (m) | $535.15M | $340.97M | (m) |
| 2024-03-31 | $745.05M | (m) | $420.75M | $324.30M | (m) |
| 2023-12-31 | $773.49M | (m) | $457.47M | $316.02M | (m) |
| 2023-09-30 | $889.15M | (m) | $647.71M | $241.44M | (m) |
| 2023-06-30 | $829.05M | (m) | $665.79M | $163.25M | (m) |
| 2023-03-31 | $600.46M | (m) | $321.40M | $279.06M | (m) |
| 2022-12-31 | $608.47M | (m) | $292.47M | $315.99M | (m) |
| 2022-09-30 | $580.18M | (m) | $263.96M | $316.23M | (m) |
| 2022-06-30 | $580.97M | (m) | $254.65M | $326.32M | (m) |
| 2022-03-31 | $528.87M | (m) | $282.56M | $246.31M | (m) |
| 2021-12-31 | $536.31M | (m) | $337.54M | $198.77M | (m) |
| 2021-09-30 | $560.30M | (m) | $310.44M | $249.86M | (m) |
| 2021-06-30 | $538.35M | (m) | $258.34M | $280.00M | (m) |
| 2021-03-31 | $541.00M | (m) | $205.03M | $335.97M | (m) |
| 2020-12-31 | $635.03M | (m) | $272.96M | $362.07M | (m) |
| 2020-09-30 | $569.38M | (m) | $240.87M | $328.52M | (m) |
| 2020-06-30 | $532.56M | (m) | $189.00M | $343.56M | (m) |
| 2020-03-31 | $495.99M | (m) | $176.07M | $319.93M | (m) |
| 2019-12-31 | $534.98M | (m) | $203.77M | $331.21M | (m) |
| 2019-09-30 | $587.18M | (m) | $261.43M | $325.76M | (m) |
| 2019-06-30 | $570.29M | (m) | $195.95M | $374.34M | (m) |
| 2019-03-31 | $582.13M | (m) | $225.23M | $356.89M | (m) |
| 2018-12-31 | $539.29M | (m) | $266.76M | $272.53M | (m) |
| 2018-09-30 | $467.09M | (m) | $216.04M | $251.05M | (m) |
| 2018-06-30 | $433.51M | (m) | $155.85M | $277.66M | (m) |
| 2018-03-31 | $404.56M | (m) | $186.50M | $218.06M | (m) |
| 2017-12-31 | $433.50M | (m) | $191.30M | $242.21M | (m) |
| 2017-09-30 | $450.10M | (m) | $165.12M | $284.98M | (m) |
| 2017-06-30 | $475.11M | (m) | $158.11M | $317.00M | (m) |
| 2017-03-31 | $476.42M | (m) | $181.31M | $295.11M | (m) |
| 2016-12-31 | $497.23M | (m) | $186.38M | $310.86M | (m) |
| 2016-09-30 | $549.46M | (m) | $202.24M | $347.22M | (m) |
| 2016-06-30 | $655.98M | (m) | $196.44M | $459.54M | (m) |
| 2016-03-31 | $625.39M | (m) | $199.98M | $425.41M | (m) |
| 2015-12-31 | $534.78M | (m) | $181.11M | $353.67M | (m) |
| 2015-09-30 | $771.76M | (m) | $222.34M | $549.42M | (m) |
| 2015-06-30 | $776.77M | (m) | $196.89M | $579.88M | (m) |
| 2015-03-31 | $747.46M | (m) | $209.31M | $538.15M | (m) |
| 2014-12-31 | $631.17M | (m) | $224.06M | $407.10M | (m) |
| 2014-09-30 | $572.57M | (m) | $136.18M | $436.39M | (m) |
| 2014-06-30 | $638.49M | (m) | $188.32M | $450.17M | (m) |
| 2014-03-31 | $552.27M | (m) | $156.32M | $395.95M | (m) |
| 2013-12-31 | $362.23M | (m) | $167.56M | $194.67M | (m) |
| 2013-09-30 | $339.43M | (m) | $173.50M | $165.92M | (m) |
| 2013-06-30 | $228.54M | (m) | $116.40M | $112.14M | (m) |
| 2013-03-31 | $221.35M | (m) | $96.96M | $124.39M | (m) |
| 2012-12-31 | $209.30M | (m) | $135.89M | $73.41M | (m) |
| 2012-09-30 | $199.45M | (m) | $132.42M | $67.03M | (m) |
| 2012-06-30 | $164.37M | (m) | $85.60M | $78.77M | (m) |
| 2012-03-31 | $190.45M | (m) | $83.60M | $106.85M | (m) |
| 2011-12-31 | $213.43M | (m) | $85.33M | $128.10M | (m) |
| 2011-09-30 | $215.56M | (m) | $89.24M | $126.33M | (m) |
| 2011-06-30 | (m) | (m) | $35.95M | (m) | (m) |
| 2011-03-31 | $201.32M | (m) | $38.39M | $162.93M | (m) |
| 2010-12-31 | (m) | (m) | $38.86M | (m) | (m) |
| 2010-09-30 | (m) | (m) | $37.26M | (m) | (m) |
| 2010-03-31 | (m) | (m) | $79.32M | (m) | (m) |
| 2009-03-31 | (m) | (m) | $86.89M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |